HHS Secretary Donna E. Shalala announced today that the Department of Health
and Human Services began notifying the first eligible families that will
receive payments from the Ricky Ray Hemophilia Relief Fund.
The initial recipients are being notified via letters as applications are
approved, consistent with the process established by HHS' Health Resources and
Services Administration (HRSA), in consultation with The National Hemophilia
Foundation, The American Federation of Hemophiliacs and the hemophiliac
advocacy group, The Committee of Ten Thousand. The application and payment
process was developed by HRSA to assure that funds will be made available to
eligible individuals as quickly as possible. Some 670 people are expected to receive money this year.
In drug news, Glaxo Wellcome Inc. has received additional reports of dispensing errors involving Lamictal ® (lamotrigine) Tablets and other prescription drugs; most of these errors have been with the prescription medication Lamisil ® (terbinafine hydrochloride) Tablets,
some of which have resulted in serious adverse events. Medication dispensing errors are a serious threat to quality health care and necessitate the combined efforts of prescribers, dispensers, manufacturers and patients to minimize their occurrence. You can get the complete prescribing information for Lamictal in this Vidyya issue, as well as information from Glaxo on how to avoid this particular medication error.
With a Senate vote on a patients' bill of rights expected in early September, American Medical Association leaders this week head to Oklahoma and Tennessee to mobilize grassroots support to pass a strong patients' bill of rights. The AMA feels the patients' rights bill is within one vote of being passed.
Finally, landmark study results are showing that the beta blocking agent carvedilol (Coreg ®) decreased mortality rates by 35 percent in patients with the most advanced stage of heart failure who were already taking standard therapy. Coreg is the first beta blocking agent to show a significant survival benefit in this patient population. These results were presented today at the European Society of Cardiologists (ESC) 22nd Annual Congress in Amsterdam.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.